10-K: Ampio Pharmaceuticals to Delist from NYSE American Amidst Program Halt and Liquidation Plans

Ampio Pharmaceuticals will voluntarily delist from the NYSE American and wind down operations after disappointing non-clinical trial results for its lead drug candidate, OA-201.

Summary

• Ampio Pharmaceuticals, a pre-revenue biopharmaceutical company, has decided to cease development of its lead drug candidate, OA-201, after recent non-clinical studies failed to show the same pain reduction benefits as earlier trials.
• The company is now focused on preserving cash to fund an orderly wind down of operations and maximize its cash position.
• Ampio plans to voluntarily delist from the NYSE American and suspend its reporting obligations under the Securities Exchange Act.
• The board of directors is considering options including liquidation and dissolution or bankruptcy.
• The company had a net loss of $8.6 million in 2023 and used $8.6 million in cash to fund operations.
• As of December 31, 2023, Ampio had $4.1 million in cash and cash equivalents and $0.9 million in an insurance recovery receivable.
• As of February 29, 2024, the company had $3.4 million in cash and cash equivalents and $0.5 million of an insurance recovery receivable.
• The company has terminated employees and third-party agreements related to the OA-201 program.
• Ampio is also pursuing resolution of pending legal proceedings, including a settlement in principle for certain class action and derivative lawsuits.

Sentiment

Score: 2

Explanation: The document indicates a very negative outlook for the company, with the cessation of its lead program, plans for delisting, and potential liquidation or bankruptcy. The sentiment is very poor from an investment perspective.

Positives

• A settlement in principle has been reached for certain legal proceedings, which is expected to be covered by insurance.
• The company is taking steps to preserve cash and maximize its cash position.
• The company has terminated its ATM agreement, which will reduce future costs.

Negatives

• The failure of the OA-201 program has led to the cessation of all preclinical and clinical development activities.
• The company is facing substantial doubt about its ability to continue as a going concern.
• The company is pursuing voluntary delisting from the NYSE American, which will likely negatively impact the stock price.
• The company is considering liquidation and dissolution or bankruptcy.
• The company has terminated employees and third-party agreements, indicating a significant reduction in operations.
• The company has no revenue and is reliant on cash reserves.

Risks

• The company's only product development opportunity has been terminated.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's cash resources may not be sufficient to cover all liabilities and fund a distribution to stockholders.
• The company is involved in ongoing legal proceedings that could negatively impact its cash position.
• The company's stock price is expected to be volatile due to delisting and deregistration.
• The company's provisional patent applications may be of limited value.
• The settlement in principle of certain legal actions is subject to a number of conditions and risks.

Future Outlook

The company is focused on preserving cash to fund an orderly wind down of operations and maximize its cash position. The board is considering options including liquidation and dissolution or bankruptcy. The company expects to suspend its reporting obligations after delisting from the NYSE American.

Management Comments

• The Board of Directors believes that more likely options include the liquidation and wind up of the Company through a dissolution pursuant to a plan of liquidation and dissolution that would be subject to Board and stockholder approval or bankruptcy.
• The Board of Directors determined to pursue voluntary delisting of Ampios common stock from the NYSE American as part of its cash conservation plan.

Industry Context

The announcement reflects the challenges faced by small biopharmaceutical companies in drug development, particularly the high risk of failure in clinical trials and the need for strong financial planning. The decision to wind down operations is not uncommon in the industry when a lead drug candidate fails to meet expectations.

Comparison to Industry Standards

• The decision to cease development of OA-201 and pursue liquidation is similar to other small biotech companies that have faced clinical trial failures, such as Omeros Corporation which recently announced a restructuring and layoffs after a clinical trial setback.
• The company's cash burn rate of approximately $8.6 million in 2023 is relatively high for a pre-revenue company, which is not uncommon in the biotech sector, but the lack of revenue and the failure of the lead program makes the situation unsustainable.
• The company's decision to delist from the NYSE American is a common strategy for companies facing financial difficulties, similar to what has been seen with other small-cap biotech companies that have struggled to maintain listing requirements.

Management Changes

Legal Proceedings

• The company is involved in a securities fraud class action, Case Number 22-cv-2105-WJM-MEH.
• The company is involved in consolidated derivative actions, Case Number 22-cv-2803-KLM.
• The company is involved in a Colorado state court derivative action, Case Number 2023CV30287.
• A settlement in principle has been reached for the securities fraud class action and the consolidated derivative actions.
• The settlements are subject to various conditions, including confirmatory discovery, negotiation and execution of full settlement agreements, and obtaining court approval.
• The settlements do not affect the ongoing investigation by the Securities and Exchange Commission.

Stakeholder Impact

• Shareholders are likely to experience a significant loss in value due to the company's delisting and potential liquidation.
• Employees have been terminated as part of the company's cost-cutting measures.
• Customers and suppliers are likely to be impacted by the company's wind-down of operations.
• Creditors may face uncertainty regarding the recovery of outstanding debts.

Next Steps

• The company will pursue voluntary delisting from the NYSE American.
• The company will suspend its reporting obligations under the Exchange Act.
• The board will evaluate options for liquidation and dissolution or bankruptcy.
• The company will continue to pursue resolution of pending legal proceedings.
• The company will finalize and execute settlement agreements and have motions for preliminary approval submitted to the relevant courts by mid-May 2024.

Key Dates

Keywords

delisting, liquidation, dissolution, bankruptcy, OA-201, clinical trials, non-clinical studies, pharmaceutical, biopharmaceutical, NYSE American, cash preservation, legal proceedings, settlement, reverse stock split